GEF-Inhibitors: New small molecules for the treatment of autoimmune and malignant diseases
Scientists at the University of Bonn have identified new small molecules which can be used for the treatment of diseases characterized by alterations of proteins which are affected by Guanine nucleotide Exchange Factors (GEFs). Proteins targeted by GEFs are involved in integrin signalling, vesicle transport, or MAPK-signalling. These processes play an important role in the modulation of the immune response. Therefore, abnormal activation of the target proteins of GEFs can cause autoimmune and tumor diseases in humans.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 0
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Breaking the Ice: Glacier Melting Alters Arctic Fjord Ecosystems
The regions of the Arctic are particularly vulnerable to climate change. However, there is a lack of comprehensive scientific information about the environmental changes there. Researchers from the Helmholtz Center…
Global Genetic Insights into Depression Across Ethnicities
New genetic risk factors for depression have been identified across all major global populations for the first time, allowing scientists to predict risk of depression regardless of ethnicity. The world’s…
Back to Basics: Healthy Lifestyle Reduces Chronic Back Pain
Low back pain is a leading cause of disability worldwide with many treatments, such as medication, often failing to provide lasting relief. Researchers from the University of Sydney’s Centre for Rural…